Tecentriq (atezolizumab) was approved in 2019 for PD-L1–positive triple-negative breast cancer (TNBC), said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Tecentriq (atezolizumab) was approved in 2019 for PD-L1–positive triple-negative breast cancer (TNBC), and approval for pembrolizumab plus chemotherapy is expected soon, as well, said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Transcript
How has immuno-oncology changed the treatment arena for patients with triple-negative disease?
We got the first immuno-oncology drug approved last year, which was Tecentriq, or atezolizumab, in combination with Abraxane [paclitaxel] for patients with PD-L1–positive triple-negative breast cancer. And earlier this year, we heard the results from the KEYNOTE-355 trial, which looked at pembrolizumab in combination with chemotherapy for patients with metastatic triple-negative breast cancer, and it's expected that that drug would get approved. So we have a couple of chemotherapy-plus-immunotherapy-based options for patients with metastatic disease.
And the other class of drug includes antibody-drug conjugates, like sacituzumab govitecan, which deliver high doses of chemotherapy to the cancer cells and thus can result in disease control. That's one example. There's ongoing research looking at other antibody-drug conjugates.
What can we learn from treatment failure to direct future research?
It's understanding the mechanisms governing resistance. If you understand why the treatment stopped working after a while, then you can address that why and build better therapies.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More